Skip to main content
SpringerLink
Log in

FDA issues warning of azithromycin-arrhythmia risk

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • FDA. FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. Internet Document : [3 pages], 12 Mar 2013. Available from: URL: http://www.fda.gov

Download references

Additional information

* see Reactions 1403 p5; 801085559

Rights and permissions

Reprints and permissions

About this article

Cite this article

FDA issues warning of azithromycin-arrhythmia risk. Reactions Weekly 1444, 5 (2013). https://doi.org/10.1007/s40278-013-2018-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-013-2018-0

Search

Navigation